Enanta Pharmaceuticals (ENTA) Other Non-Current Assets (2012 - 2026)

Enanta Pharmaceuticals has reported Other Non-Current Assets for 15 years, with the latest figure at $144000.0 in Q1 2026.

• For the quarter ending Q1 2026, Other Non-Current Assets rose 46.94% year-over-year to $144000.0; the trailing twelve-month figure through Mar 2026 stood at $144000.0 (up 46.94% YoY), and the FY2025 full-year result was $92000.0, down 97.26% from the prior year.
• Other Non-Current Assets for Q1 2026 stood at $144000.0, up from $93000.0 in the prior quarter.
• The five-year high for Other Non-Current Assets was $4.0 million in Q2 2022, with the low at $92000.0 in Q3 2025.
• Historically, Other Non-Current Assets has averaged $1.9 million across 5 years, with a median of $830000.0 in 2023.
• Annual changes were most pronounced in 2022 — Other Non-Current Assets soared 4213.04% — and 2025, when it slumped 97.26%.
• Enanta Pharmaceuticals' Other Non-Current Assets stood at $4.0 million in 2022, then sank by 80.72% to $765000.0 in 2023, then surged by 339.22% to $3.4 million in 2024, then plunged by 97.23% to $93000.0 in 2025, then soared by 54.84% to $144000.0 in 2026.
• The last three Other Non-Current Assets figures came in at $144000.0 (Q1 2026), $93000.0 (Q4 2025), and $92000.0 (Q3 2025), per Business Quant data.